The Pandora’s Box of novel technologies that may revolutionize lung cancer

Rad, HS; Rad, HS; Shiravand, Y; Radfar, P; Arpon, D; Warkiani, ME; O'Byrne, K; Kulasinghe, A

The Pandora’s Box of novel technologies that may revolutionize lung cancer

Rad, HS Rad, HS Shiravand, Y Radfar, P Arpon, D Warkiani, ME O'Byrne, K Kulasinghe, A

Permalink

Publisher:: Elsevier
Publication Type:: Journal Article
Citation:: Lung Cancer, 2021, 159, pp. 34-41
Issue Date:: 2021-07-19

Recently Added

	Filename	Description	Size
	1-s2.0-S0169500221004712-main.pdf	Published version	2.73 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is new to OPUS and is not currently available.

Full metadata record

Field	Value	Language
dc.contributor.author	Rad, HS
dc.contributor.author	Rad, HS
dc.contributor.author	Shiravand, Y
dc.contributor.author	Radfar, P
dc.contributor.author	Arpon, D
dc.contributor.author	Warkiani, ME
dc.contributor.author	O'Byrne, K
dc.contributor.author	Kulasinghe, A
dc.date.accessioned	2022-03-08T06:16:07Z
dc.date.available	2021-06-27
dc.date.available	2022-03-08T06:16:07Z
dc.date.issued	2021-07-19
dc.identifier.citation	Lung Cancer, 2021, 159, pp. 34-41
dc.identifier.issn	0169-5002
dc.identifier.issn	1872-8332
dc.identifier.uri	http://hdl.handle.net/10453/155073
dc.description.abstract	Non-small cell lung cancer (NSCLC) is one of the most common cancers globally and has a 5-year survival rate ~20%. Immunotherapies have demonstrated long-term and durable responses in NSCLC patients, although they appear to be effective in only a subset of patients. A more comprehensive understanding of the underlying tumour biology may contribute to identifying those patients likely to achieve optimal outcomes. Profiling the tumour microenvironment (TME) has shown to be beneficial in addressing fundamental tumour-immune cell interactions. Advances in multiplexing immunohistochemistry and molecular barcoding has led to recent advances in profiling genes and proteins in NSCLC. Here, we review the recent advancements in spatial profiling technologies for the analysis of NSCLC tissue samples to gain new insights and therapeutic options for NSCLC. The combination of spatial transcriptomics combined with advanced imaging is likely to lead to deep insights into NSCLC tissue biology, which can be a powerful tool to predict likelihood of response to therapy.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Elsevier
dc.relation.ispartof	Lung Cancer
dc.relation.isbasedon	10.1016/j.lungcan.2021.06.022
dc.rights	This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
dc.rights	info:eu-repo/semantics/restrictedAccess
dc.subject	1103 Clinical Sciences, 1112 Oncology and Carcinogenesis
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.mesh	Carcinoma, Non-Small-Cell Lung
dc.subject.mesh	Humans
dc.subject.mesh	Immunohistochemistry
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Lung Neoplasms
dc.subject.mesh	Tumor Microenvironment
dc.subject.mesh	Humans
dc.subject.mesh	Carcinoma, Non-Small-Cell Lung
dc.subject.mesh	Lung Neoplasms
dc.subject.mesh	Immunotherapy
dc.subject.mesh	Immunohistochemistry
dc.subject.mesh	Tumor Microenvironment
dc.title	The Pandora’s Box of novel technologies that may revolutionize lung cancer
dc.type	Journal Article
utslib.citation.volume	159
utslib.location.activity	Ireland
utslib.for	1103 Clinical Sciences
utslib.for	1112 Oncology and Carcinogenesis
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	/University of Technology Sydney/Strength - IBMD - Initiative for Biomedical Devices
pubs.organisational-group	/University of Technology Sydney/Centre for Health Technologies (CHT)
utslib.copyright.status	recently_added	*
pubs.consider-herdc	false
dc.date.updated	2022-03-08T06:16:06Z
pubs.publication-status	Published
pubs.volume	159

Abstract:

Non-small cell lung cancer (NSCLC) is one of the most common cancers globally and has a 5-year survival rate ~20%. Immunotherapies have demonstrated long-term and durable responses in NSCLC patients, although they appear to be effective in only a subset of patients. A more comprehensive understanding of the underlying tumour biology may contribute to identifying those patients likely to achieve optimal outcomes. Profiling the tumour microenvironment (TME) has shown to be beneficial in addressing fundamental tumour-immune cell interactions. Advances in multiplexing immunohistochemistry and molecular barcoding has led to recent advances in profiling genes and proteins in NSCLC. Here, we review the recent advancements in spatial profiling technologies for the analysis of NSCLC tissue samples to gain new insights and therapeutic options for NSCLC. The combination of spatial transcriptomics combined with advanced imaging is likely to lead to deep insights into NSCLC tissue biology, which can be a powerful tool to predict likelihood of response to therapy.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/155073